HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Nadh

HCID 439153
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
58-68-4
Standard SMILES
NC(=O)C1=CN([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](O)[C@@H]3O)[C@@H](O)[C@H]2O)C=CC1
InChIKey
BOPGDPNILDQYTO-NNYOXOHSSA-N
Molecular formula
C21H29N7O14P2
Average molar mass
665.4 g/mol
Monoisotopic mass
665.12477262

Overview

NADH is a coenzyme found in all living cells; consists of two nucleotides joined through their 5'-phosphate groups, with one nucleotide containing an adenine base and the other containing nicotinamide. It has a role as a cofactor and a fundamental metabolite. It is a NAD and a NAD(P)H. It is a conjugate acid of a NADH(2-).

Names & identifiers

Preferred name
Nadh
IUPAC
[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate
English name
dihydrodiphosphopyridine nucleotide
Molecular formula
C21H29N7O14P2
Molecular weight
665.44

Names & synonyms

NADHDPNH58-68-4beta-NADH1,4-Dihydronicotinamide adenine dinucleotideNADH2dihydronicotinamide adenine dinucleotideReduced nicotinamide adenine diphosphateReduced nicotinamide-adenine dinucleotideReduced Nicotinamide Adenine Dinucleotide[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoyl-4H-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate4J24DQ0916
Show more names
NICOTINAMIDE ADENINE DINUCLEOTIDEdihydrocozymaseReduced formβ-NADH, DPNH, NADHReduced codehydrase ITestosterone 17β-dehydrogenase
Nicotinamide-adenine dinucleotide, reducednicotinamide adenine dinucleotide (reduced)CHEBI:16908DTXSID30889320[({[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy]({[(2R,3S,4R,5R)-5-(3-carbamoyl-1,4-dihydropyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy})phosphinic acidAdenosine 5'-(trihydrogen diphosphate), P'->5'-ester with 1,4-dihydro-1-beta-D-ribofuranosyl-3-pyridinecarboxamideNAD reduced(((((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl)methoxy)(hydroxy)phosphoryl)oxy)((((2R,3S,4R,5R)-5-(3-carbamoyl-1,4-dihydropyridin-1-yl)-3,4-dihydroxyoxolan-2-yl)methoxy))phosphinic acid

Properties

Computed structural properties

XLogP
-5.7
Topological polar surface area
318 Ų
Hydrogen bond donors
8
Hydrogen bond acceptors
19
Rotatable bonds
11
Heavy atoms
44
Formal charge
0
Complexity
1,230

Experimental & physicochemical properties

DrugsPharmaceuticals -> Listed in ZINC15
Melting Point · 2 items

140.0-142.0 °C

140.0 - 142.0 °C

Physical DescriptionSolid

Physicochemical properties

Boiling point
1081.8 · 1081.8±75.0 °C(Predicted)
Density
2.18 · 2.18±0.1 g/cm3(Predicted)
solubility
Water (Slightly)
pka
1.13 · 1.13±0.50(Predicted)
form
Solid
color
White to Off-White
ex/em
340 nm; · λex 340 nm; λem 466 nm
Stability
Light Sensitive, Temperature Sensitive
InChIKey
BOPGDPNILDQYTO-NNYOXOHSSA-N
FDA UNII
4 J24DQ0916 · 4J24DQ0916

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

Hazard information

Regulatory Information · 2 items

Chemical: Adenosine 5′-(trihydrogen diphosphate), P′.fwdarw.5′-ester with 1,4-dihydro-1-.beta.-D-ribofuranosyl-3-pyridinecarboxamide

Adenosine 5'-(trihydrogen diphosphate), P'→5'-ester with 1,4-dihydro-1-.beta.-D-ribofuranosyl-3-pyridinecarboxamide, disodium salt: Does not have an individual approval but may be used under an appropriate group standard

Other Safety InformationEvaluation - Chemicals that are unlikely to require further regulation to manage risks to environment

Safety data

tsca
TSCA listed

Chemistry & industry

Pharmacology

Pharmacodynamics · 1 item

A coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage. It is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by being alternately oxidized (NAD+) and reduced (NADH). The action of supplemental NADH is unclear. Oral NADH supplementation has been used to combat simple fatigue as well as such mysterious and energy-sapping disorders as chronic fatigue syndrome and fibromyalgia. Researchers are also studying the value of NADH supplements for improving mental function in people with Alzheimer's disease, and minimizing physical disability and relieving depression in people with Parkinson's disease. Some healthy individuals also take NADH supplements orally to improve concentration and memory capacity, as well as to increase athletic endurance. However, to date there have been no published studies to indicate that using NADH is in any way effective or safe for these purposes.

Mechanism of Action · 1 item

NADH is synthesized by the body and thus is not an essential nutrient. It does require the essential nutrient nicotinamide for its synthesis, and its role in energy production is certainly an essential one. In addition to its role in the mitochondrial electron transport chain, NADH is produced in the cytosol. The mitochondrial membrane is impermeable to NADH, and this permeability barrier effectively separates the cytoplasmic from the mitochondrial NADH pools. However, cytoplasmic NADH can be used for biologic energy production. This occurs when the malate-aspartate shuttle introduces reducing equivalents from NADH in the cytosol to the electron transport chain of the mitochondria. This shuttle mainly occurs in the liver and heart.

Absorption, Distribution and ExcretionUnclear how much of an administered dose is absorbed.
Tissue LocationsBladder
Cellular LocationsEndoplasmic reticulum
Metabolite Pathways11-beta-hydroxylase deficiency (CYP11B1)

Related reactions

141 records
New reaction record
HRID 7345 reaction equation
HRID 7345As productAs reactant
HRID 17763 reaction equation
HRID 17763As reactant
HRID 27575 reaction equation
HRID 27575As reactant
HRID 27576 reaction equation
HRID 27576As productAs reactant
HRID 27577 reaction equation
HRID 27577As reactant
HRID 27683 reaction equation
HRID 27683As reactant
HRID 48903 reaction equation
HRID 48903As reactant
HRID 58507 reaction equation
HRID 58507As reactant
PreviousPage 1 of 18

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes

Database identifiers

CAS
58-68-4、606-68-8
PubChem CID
439153
DTXSID
DTXSID30889320
ChEMBL
CHEMBL1234616
ChEBI
CHEBI:16908
UNII
4J24DQ0916
EC Number
200-393-0
Nikkaji
J213.546I
EPA Substance Registry System
5 · Adenosine 5'-(trihydrogen diphosphate), P'.fwdarw.5'-ester with 1,4-dihydro-1-.beta.-D-ribofuranosyl-3-pyridinecarboxamide (58-68-4)
TSCA
TSCA listed

Uses & manufacturing

General Manufacturing InformationAdenosine 5'-(trihydrogen diphosphate), P'.fwdarw.5'-ester with 1,4-dihydro-1-.beta.-D-ribofuranosyl-3-pyridinecarboxamide: INACTIVE
Applications · 1 item

Usesb-NADH-d4 is labelled b-NADH (N201480, Disodium salt). b-NADH is one of the biologically active forms of nicotinic acid. Serves as a coenzyme of hydrogenases and dehydrogenases. NAD usually acts as a hydrogen acceptor, forming NADH which then serves as a hydrogen donor in the respiratory chain. Present in living cells primarily in the reduced form (NADPH) and is involved in synthetic reactions.

Upstream & downstream products

Upstream raw materials

Nicotinyl chloride hydrochloride

Downstream products

NADPH

Additional notes

DefinitionChEBI: A coenzyme found in all living cells; consists of two nucleotides joined through their 5'-phosphate groups, with one nucleotide containing an adenine base and the other containing nicotinamide.